GlassScriptPhysician profile
Bradley Mackler
NPI 1356430854
$3,234.22
in general payments reported to CMS, 2019-2025
21 companies · $388 in 2025
The $388 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,013 · 2020: $343 · 2021: $534 · 2022: $358 · 2023: $446 · 2024: $151 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.70 | 2019-2025 | |
| Gilead Sciences, INC. | $489.25 | 2019-2023 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $287.20 | 2019-2025 | Entyvio |
| Intercept Pharmaceuticals, INC. | $275.27 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.66 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $177.53 | 2024-2025 | Voquezna |
| Pfizer INC. | $160.64 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Eisai INC. | $123.79 | 2019 | |
| Ferring Pharmaceuticals INC. | $120.84 | 2023 | Rebyota |
| Novo Nordisk INC | $107.91 | 2025 | Wegovy |
| Janssen Biotech, INC. | $103.72 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Dova Pharmaceuticals | $84.77 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $72.29 | 2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $56.42 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $31.72 | 2019-2020 | |
| Genzyme Corporation | $28.60 | 2025 | |
| Daiichi Sankyo INC. | $20.80 | 2021 | |
| Medtronic, INC. | $19.64 | 2023 | Interstim |
| Madrigal Pharmaceuticals | $17.80 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Mackler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.